Abstract 4869: Chromosomal and telomeric biomarkers of normal tissue injury to evaluate risk of secondary malignancy following IMRT for prostate cancer

An overall intent of radiotherapy is to precisely target tumor cells, while minimizing exposures to surrounding normal tissue. Despite successes, there is growing concern that an unacceptably large volume of normal tissue is unavoidably exposed. Chromosome aberrations provide a direct measure of ionizing radiation (IR)-induced DNA damage, as well as an indirect measure of future risk since they are associated with virtually all known cancers. Such structural variants (SVs) include translocations (rearrangements between chromosomes) and inversions (rearrangements within chromosomes), the latter being recently identified as part of a distinctive mutational signature associated with radiation therapy-induced second malignancies. Directional Genomic Hybridization (dGH), is a strand-specific cytogenomics-based methodology for cell-by-cell, high-resolution detection of all SVs, particularly inversions, which when combined with compatible subtelomere probes (Telo-dGH), can be used to distinguish inversions from recombination events (sister chromatid exchange) involving chromosomal termini. Telomeres are critical structural elements that serve to protect the physical ends of chromosomes. Dysfunctional telomeres are associated with instability and carcinogenesis, as well as with a variety of other age-related pathologies (e.g., cardiovascular disease). We are validating Telo-dGH as a prospective “personalized” approach of evaluating normal tissue injury, and therefore future risk, associated with radiation therapy - regardless of tumor type or treatment modality. Here, we report results of monitoring prostate cancer patients before and after intensity-modulated radiation therapy (IMRT) to assess radiosensitivity (toxicity), as well as risk of secondary malignancy and other degenerative late effects. Such a strategy has the potential to better inform patient treatment and management decisions based on predicted individual risk. Citation Format: Jared J. Luxton, Miles J. McKenna, Lynn Taylor, Gregory P. Swanson, Susan M. Bailey. Chromosomal and telomeric biomarkers of normal tissue injury to evaluate risk of secondary malignancy following IMRT for prostate cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 4869.